UC Davis

UC Davis Previously Published Works

Title

Pharmacogenetics and interstitial lung disease.

Permalink

<https://escholarship.org/uc/item/86p2j949>

Journal

Current opinion in pulmonary medicine, 22(5)

ISSN

1070-5287

Authors

Oldham, Justin M
Noth, Imre
Martinez, Fernando J

Publication Date

2016-09-01

DOI

10.1097/mcp.0000000000000289

Peer reviewed

Pharmacogenetics and interstitial lung disease

Justin M. Oldham^a, Imre Noth^b, and Fernando J. Martinez^c

Purpose of review

Interstitial lung disease (ILD) is comprised of a heterogeneous group of disorders with highly variable natural histories and response to therapies. Pharmacogenetics focuses on the variability in drug response because of the presence of genetic factors that influence drug metabolism or disease activity. In this article, we review relevant drug-specific and disease-specific polymorphisms that may influence therapeutic response, and then highlight a recently identified drug–gene interaction in patients with idiopathic pulmonary fibrosis (IPF).

Recent findings

The emergence of high-throughput genomic technology has allowed for identification of gene polymorphisms associated with susceptibility to specific disease states, including IPF and several connective tissue diseases known to cause ILD. IPF risk loci span a diverse group of genes, while most associated with connective tissue disease are critical to immune signaling. A recent pharmacogenetic analysis of patients enrolled in an IPF clinical trial identified a variant within *TOLLIP* to be associated with differential response to N-acetylcysteine therapy.

Summary

Though few pharmacogenetic investigations have been conducted in patients with ILD to date, ample opportunities for pharmacogenetic exploration exist in this patient population. Such exploration will advance our understanding of specific ILDs and help usher in an era of personalized medicine.

Keywords

connective tissue disease, idiopathic pulmonary fibrosis, interstitial lung disease, pharmacogenetics

INTRODUCTION

Pharmacogenetics, the study of variability in treatment response because of an individual's genetic constitution, traces its origins to the mid-20th century [1,2]. Pharmacogenomics, often used interchangeably with pharmacogenetics, focuses on how a drug influences gene expression across the entire genome [1,3]. Whereas pharmacogenomic investigation provides valuable mechanistic insight and facilitates the development of novel therapies, pharmacogenetic investigation identifies individuals predisposed to benefit or harm from a particular therapy and, therefore, serves as a lynchpin of personalized medicine.

Pharmacogenetic investigation requires one or more genetic biomarkers with which to stratify a population to test for differential drug effect. Single nucleotide polymorphisms (SNPs) serve as the most commonly utilized pharmacogenetic biomarkers, but larger structural variants, including insertions, deletions, copy number variations and inversions have also been explored [4–6]. The frequency of gene variants can vary substantially across genetic ancestral groups, and needs to be taken into

account during the study design phase of pharmacogenetic investigation. Pharmacogenetic biomarkers are chosen because of a plausible influence on a drug's pharmacokinetics – distribution, elimination, absorption, and metabolism – or pharmacodynamics – modulation of a disease-causing or disease-palliating molecular pathway [3].

Within pulmonary medicine, pharmacogenetic investigation has shed light on important drug–gene interactions among individuals with asthma [7–10] and chronic obstructive pulmonary disease [11–13]. Less is known about the role pharmacogenetics

^aDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, The University of California at Davis, Sacramento, California, ^bDepartment of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois and ^cDepartment of Internal Medicine, Weill Cornell Medical School, New York City, New York, USA

Correspondence to Justin M. Oldham, MD, MS, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, The University of California at Davis, 4150 V Street Suite 3400, Sacramento, CA 95817, USA. Tel: +1 916 734 8994; e-mail: joldham@ucdavis.edu

Curr Opin Pulm Med 2016, 22:000–000

DOI:10.1097/MCP.0000000000000289

KEY POINTS

- Pharmacogenetic investigation has the potential to guide therapeutic selection in patients with ILD.
- Polymorphisms within genes critical to drug processing or disease activity represent relevant genetic biomarkers with which to conduct pharmacogenetic investigation
- N-acetylcysteine may be an effective therapy for genetically predisposed individuals with IPF.

plays among patients with interstitial lung disease (ILD). This paucity of data stems from multiple factors. First and foremost is the phenotypic heterogeneity of the disease processes that comprise ILD. Despite shared clinical, radiographic, and pathologic features, the natural history of individual ILDs, along with their response to therapy, varies widely [14–19]. Also contributing is the low overall disease incidence of ILD, estimated to be 30/100 000 in the United States. [20] Together these factors have restricted therapeutics research to only the most common ILDs, including idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated ILD (CTD-ILD).

Despite these challenges, opportunities abound for pharmacogenetic discovery in patients with ILD. Easily acquired blood samples along with paired clinical data from patient registries and clinical trial datasets provide the components necessary to explore clinically relevant drug–gene interaction in this patient population. In this review, we highlight drug-specific polymorphisms known to influence pharmacokinetics or dynamics and provide an overview of polymorphisms associated with specific ILDs that may influence therapeutic response. We then review past pharmacogenetic testing performed in patients with IPF and highlight a recently identified drug–gene interaction in this population.

DRUG-SPECIFIC PHARMACOGENETIC BIOMARKERS

ILD etiology guides therapeutic selection in this patient population. ILDs characterized predominantly by inflammation, including most CTD-ILDs, are often treated with immunomodulatory compounds, such as corticosteroids, azathioprine, mycophenolate mofetil, and tacrolimus. The antifibrotic agents pirfenidone and nintedanib were recently approved for the treatment of IPF, which represents a fibrotic-predominant process. These therapies also hold promise for patients with systemic sclerosis, a connective tissue disease (CTD) in which fibrosis predominates, and are under investigation.

Although the aforementioned therapies have unique mechanisms of action, all undergo extensive hepatic processing and may, therefore, be influenced by polymorphisms within genes involved in this process. Of particular importance are variants within genes encoding hepatic cytochrome p450 protein superfamily, uridine 5'-triphosphate glucuronosyltransferases, N-acetyltransferases, and sulfontransferases [21]. Because the role each of these enzymes plays in drug metabolism has been extensively characterized, their genetic structure and functional polymorphisms are well documented. Drug-specific polymorphisms with potential pharmacogenetic relevance are outlined below.

Corticosteroids

After the binding of corticosteroid to the glucocorticoid receptor, this complex is transported into the nucleus of the cell where it inhibits transcription of proinflammatory genes and induces transcription of anti-inflammatory genes [22]. Corticosteroids are commonly used as an adjunct to other immunomodulatory therapies in patients with CTD-ILD [23]. Polymorphisms within *NR3C1*, which encodes the glucocorticoid receptor, have been associated with increased glucocorticoid sensitivity in healthy adults and corticosteroid dependency in children with inflammatory bowel disease [24,25]. Additionally, polymorphisms within *CRHR1*, encoding the corticotrophin-releasing hormone receptor, *STIP1*, encoding an adaptor protein within the intracellular glucocorticoid receptor heterocomplex and *TBX21*, encoding a transcription factor that influences T-lymphocyte production, have been associated with differential inhaled corticosteroid responsiveness in patients with asthma [26–28].

Azathioprine

A prodrug of mercaptopurine, azathioprine inhibits B and T lymphocyte production through disruption of DNA synthesis. Azathioprine is commonly used to treat a wide variety of autoimmune conditions, including ILD associated with rheumatoid arthritis (RA) [29], Sjogren's disease [30], systemic sclerosis [18,31,32] and myositis [33–35]. To become the metabolically active mercaptopurine, azathioprine requires activation by the enzyme thiopurine methyl-transferase (TPMT). Polymorphisms within *TPMT*, the gene encoding the TPMT enzyme, have been shown to modulate drug bioavailability and adverse event risk, including bone marrow toxicity and gastrointestinal intolerance [36,37]. Such findings have led to consensus statements across multiple specialties that offer practice guidelines

based on *TPMT* genotype testing [38–41]. Genes encoding other enzymes critical to azathioprine processing, including aldehyde oxidase and xanthine oxidase, also offer potential for pharmacogenetic investigation in ILD, as polymorphisms within these genes have been linked to differential azathioprine response among individuals with inflammatory bowel disease [42].

Mycophenolate mofetil

Like azathioprine, mycophenolate mofetil is commonly used to treat CTD-ILD and has been shown to preserve lung function in this population [43–45]. Mycophenolate mofetil is rapidly converted to mycophenolic acid (MPA), which then blocks B and T-lymphocyte proliferation through selective inhibition of inosine monophosphate dehydrogenase. Polymorphisms within inosine monophosphate dehydrogenase have been shown to markedly reduce the in-vitro antiproliferative effects of MPA [46] and have the potential to influence drug response. MPA is subsequently inactivated by hepatic UDP-glucuronosyltransferase (UGT). Polymorphisms within *UGT1A9* have been associated with a significant increase in UDP-glucuronosyltransferase activity, thereby reducing the amount of circulating bioactive MPA [47]. Although these polymorphisms still have unclear clinical consequences, further investigation is warranted.

Tacrolimus

A calcineurin inhibitor used most often to prevent solid organ transplant rejection, tacrolimus has also been shown to slow pulmonary function decline and improve outcomes in patients with myositis-associated ILD [48–50]. Polymorphisms within cytochrome p450 genes *CYP3A5* and *CYP3A4* have been shown to influence the bioavailability of tacrolimus [51]. Absorption of tacrolimus may also be influenced by the presence of polymorphisms within the *MDR1* gene, which encodes a cellular efflux pump protein [52].

Pirfenidone and nintedanib

These antifibrotic agents were recently approved in the United States for the treatment of patients with IPF after phase 3 clinical trials demonstrated efficacy in the slowing of pulmonary function decline [53–55]. Although its exact mechanism of action remains incompletely characterized, pirfenidone has been shown to reduce human fibroblast proliferation and myofibroblast differentiation through attenuation of transforming growth

factor- β expression (TGF- β) and downstream signaling pathways [56,57]. Polymorphisms within TGF- β have been linked to an increased risk of pulmonary fibrosis in patients with sarcoidosis and liver fibrosis in those with hepatitis C and alcoholic abuse [58,59], raising the question of whether pirfenidone may differentially affect patients with IPF carrying these polymorphisms.

Nintedanib attenuates myofibroblast proliferation through inhibition of receptors for fibroblast growth factor (FGFR) and platelet-derived growth factor [60]. Polymorphisms within several fibroblast growth factors and platelet-derived growth factor have been linked to various types of cancer, including colon [61], breast [62] and thyroid [63]. Whether the presence of such polymorphisms in patients with IPF would affect nintedanib efficacy remains unknown. A complete list of drug-specific biomarkers with potential pharmacogenetic relevance is shown in Table 1.

DISEASE-SPECIFIC PHARMACOGENETIC BIOMARKERS

The emergence and rapid expansion of high-throughput genomic technology has led to the identification of many novel genetic loci associated with specific disease states. Based on the assumption that genes at these loci contribute to disease onset and/or activity, polymorphisms within these genes have the potential to influence the pharmacodynamics of therapies used to treat the disease [64].

Idiopathic pulmonary fibrosis

Within ILD, IPF remains the best characterized to date. Among individuals with familial interstitial pneumonia (FIP), the heritable form of IPF, rare mutations within genes involved in surfactant production, [65–69] and telomere stability [70,71] were the first gene variants to be identified in IPF. More recently, two groups identified rare mutations in *RTEL1*, which encodes an important regulator of telomere elongation, to be associated with FIP susceptibility using whole-exome sequencing [72*,73*]. Mutations within *PARN*, which encodes an exoribonuclease involved in mRNA processing, was also found to segregate with FIP using this approach [73*]. The rare nature of these mutations will likely limit their utility in pharmacogenetic modeling, but similar effects along shared pathways may allow for aggregation of certain mutations to generate larger cohorts.

Among patients with sporadic IPF, numerous genetic and genomic investigations have identified common gene variants associated IPF susceptibility

Table 1. Drug-specific polymorphisms with potential pharmacogenetics relevance

Drug	SNP	MAF ^a	Chromosome	Gene	Protein	Reference
Corticosteroids	rs860457	0.22	5	<i>NR3C1</i>	Glucocorticoid receptor	[24]
	rs6190	0.01				
	rs1876828	0.09	17	<i>CRHR1</i>	Corticotropin-releasing factor receptor 1	[26]
	rs242941	0.32				
	rs4980524	0.39	11	<i>STIP1</i>	Stress-induced phosphoprotein 1	[27]
	rs6591838	0.24				
	rs2236647	0.44				
Azathioprine	rs2240017	0.05	17	<i>TBX21</i>	T-box transcription factor TBX21	[28]
	rs1800462	<0.01	6	<i>TPMT</i>	Thiopurine S-methyltransferase	[37]
	rs1800460	0.01				
	rs1142345	0.04				
	rs55754655	0.11	2	<i>AOX1</i>	Aldehyde oxidase 1	[42]
Mycophenolate mofetil	rs4407290	0.04	2	<i>XDH</i>	Xanthine dehydrogenase	[42]
	rs11706052	0.05	3	<i>IMPDH2</i>	Inosine-5'-monophosphate dehydrogenase 2	[46]
	rs6714486	0.07	2	<i>UGT1A9</i>	UDP-glucuronosyltransferase 1–9	[47]
	rs17868320	0.02				
Tacrolimus	rs776746	0.38	7	<i>CYP3A5</i>	Cytochrome P450 3A5	[51,52]
	rs2740574	0.23	7	<i>CYP3A4</i>	Cytochrome P450 3A4	[51]
	rs1045642	0.39	7	<i>MDR1</i>	Multidrug resistance protein 1	[52]
Pirfenidone	rs3917165	0.05	14	<i>TGFβ3</i>	Transforming growth factor β-3	[58]
	rs3917200	0.15				
	rs1800471	0.05	19	<i>TGFβ1</i>	Transforming growth factor β-1	[59]
Nintedanib	rs351855	0.3	5	<i>FGFR4</i>	Fibroblast growth factor receptor 4	[61]
	rs2981582	0.4	10	<i>FGFR2</i>	Fibroblast growth factor receptor 2	[62]
	rs6554162	0.41	4	<i>PDGFRA</i>	Platelet-derived growth factor receptor α	[63]
	rs1800812	0.28				

MAF, minor allele frequency; SNP, single nucleotide polymorphisms.

^aBased on 1000 Genomes Project data (www.1000genomes.org). Actual MAF will vary depending on ancestral background of study population.

(Table 2) [74–81,82[■],83–85]. The short arm of chromosome 11 has received considerable attention, as two genes strongly associated with IPF susceptibility, *TOLLIP* and *MUC5B*, reside at this locus [74–76]. *TOLLIP* encodes Toll-interacting protein, which acts to inhibit Toll-like receptor (TLR) signaling. Several TLRs are active in the lung, including TLR2 and TLR4, and have been shown to be vital mediators of the innate and adaptive immune response [86–90]. *MUC5B* encodes a highly glycosylated protein that contributes to airway mucus production and also functions to maintain immune homeostasis [87,91,92]. In addition to their association with IPF susceptibility, two SNPs – rs5743890 within *TOLLIP* and rs35 705 950 within *MUC5B* – are associated with differential survival [74,93].

Additional loci linked to IPF by genome-wide association study (GWAS) and other genetic investigations, include MDGA2 [74], SPPL2C [74], MAPT [76], LRRC34 [76], FAM13A [76], DSP [76], OBFC1

[76], MUC2 [76], ATP11A [76], DPP9 [76], TERT [76,77], IL-8 [78], IL1RN [79,80], TNF-α [80], HLA-DRB1 [81], HSP70 [82[■]], and CDKN1A [83]. Although identification of these variants has advanced our understanding of how IPF develops, few have been shown to predict survival. The highly variable natural history of IPF, whereby some patients remain stable over many years, others progress steadily and some die from rapidly progressive disease, suggests that some genes may contribute to disease onset whereas others contribute to disease progression [94–96]. Indeed, several polymorphisms associated with disease activity, but not susceptibility, have been identified within TP53 [83], TLR3 [84], and TGFβ1 [85].

Connective tissue disease-associated interstitial lung disease

Although several GWAS have been conducted in patients with CTD, none have been performed

Table 2. IPF-associated polymorphisms with potential pharmacogenetics relevance

SNP	MAF ^a	Chromosome	Gene	Protein	References
rs5743894	0.2	11	<i>TOLLIP</i>	Toll-interacting protein	[74]
rs5743890	0.1				[74]
rs7144383	0.13	14	<i>MDGA2</i>	MAM domain-containing glycosylphosphatidylinositol anchor protein 2	[74]
rs17690703	0.2	17	<i>SPPL2C</i>	Signal peptide peptidase-like 2C	[74]
rs35705950	0.38	11	<i>MUC5B</i>	Mucin-5B	[74–76]
rs1981997	0.17	17	<i>MAPT</i>	Microtubule-associated protein tau	[76]
rs6793295	0.32	3	<i>LRRC34</i>	Leucine-rich repeat-containing protein 34	[76]
rs2609255	0.26	4	<i>FAM13A</i>	Protein FAM13A	[76]
rs2076295	0.54	6	<i>DSP</i>	Desmoplakin	[76]
rs11191865	0.45	10	<i>OBFC1</i>	CST complex subunit <i>STN1</i>	[76]
rs7934606	0.52	11	<i>MUC2</i>	Mucin-2	[76]
rs1278769	0.2	13	<i>ATP11A</i>	Probable phospholipid-transporting ATPase 1H	[76]
rs12610495	0.34	19	<i>DPP9</i>	Dipeptidyl peptidase 9	[76]
rs2736100	0.43	5	<i>TERT</i>	Telomerase reverse transcriptase	[76,77]
rs4073	0.34	4	<i>IL-8</i>	IL-8	[78]
rs2637988	0.47	2	<i>IL1RN</i>	IL-1 receptor antagonist protein	[79]
rs419598	0.28	2			[80]
rs1800629	0.22	6	<i>TNF-α</i>	Tumour necrosis factor	[80]
rs3135388	0.2	6	<i>HLA-DRB1</i>	HLA class II histocompatibility antigen, DRB1–1 β chain	[81]
rs2075800	0.46	6	<i>HSPA1L</i>	Heat shock 70 kDa protein 1-like	[82 [■]]
rs2227956	0.01	6			[82 [■]]
rs1043618	0.22	6	<i>HSPA1A</i>	Heat shock 70 kDa protein 1A	[82 [■]]
rs1061581	0.41	6	<i>HSPA1B</i>	Heat shock 70 kDa protein 1B	[82 [■]]
rs733590	0.47	6	<i>CDKN1A</i>	Cyclin-dependent kinase inhibitor 1	[83]
rs12951053	0.06	17	<i>TP53</i>	Cellular tumour antigen p53	[83]
rs12602273	0.07	17			[83]
rs3775291	0.28	4	<i>TLR3</i>	Toll-like receptor 3	[84]
rs1800470	0.41	19	<i>TGF-β1</i>	Transforming growth factor β-1	[85]

MAF, minor allele frequency.

^aBased on population of reference cited. Actual MAF will vary depending on ancestral background of study population.

in specifically in patients with CTD-associated ILD. But because immune-mediated mechanisms are believed to be responsible for ILD development in these patients, polymorphisms associated with specific disease states may serve as relevant pharmacogenetic biomarkers (Table 3). Among the best-characterized CTDs is RA. In 2010, investigators conducted a GWAS meta-analysis in over 12 000 RA cases that confirmed known susceptibility loci at *PTPN22*, *CTLA4*, *TNFAIP3*, and *CD40*. This study also identified SNPs within *IL6ST*, *SPRED2*, *RBPI*, *CCR6*, *IRF5*, and *PXK* to be novel risk loci and SNPs within *IL2RA*, *CCL21*, and *AFF3* to be novel risk alleles within known risk loci [97].

GWAS in other CTDs have also demonstrated a strong association between disease susceptibility and polymorphisms within genes involved in immune signaling. A GWAS conducted in over 2 000 patients

with systemic sclerosis identified several risk loci within the major histocompatibility complex (MHC) on chromosome 6 and at *CD247*, *IRF5*, and *STAT4* [98]. MHC SNPs have also been strongly associated with disease susceptibility in patients with poly and dermatomyositis, as have risk loci at *PLCL1*, *BLK*, and *CCL21* [99,100]. Substantial overlap in risk loci exists between the aforementioned CTDs and patients with Sjogren's syndrome, which can result in several types of lung disorders, including ILD. In a GWAS of patients with Sjogren's syndrome, risk loci were again identified within MHC genes, along with *IRF5*, *BLK*, and *STAT5*. A novel risk locus was also identified at *IL12A* [101]. Because the overwhelming majority of SNPs associated with CTD lie within genes critical to immune signaling, such polymorphisms have a high potential to influence the response to immunomodulatory therapy.

Table 3. CTD-ILD-associated polymorphisms with potential pharmacogenetics relevance

CTD	SNP	MAF ^a	Chromosome	Gene	Protein	Reference
RA	rs2476601	0.1	1	PTPN22	Tyrosine-protein phosphatase nonreceptor type 22	[97]
	rs11676922	0.49	2	AFF3	AF4/FMR2 family member 3	
	rs3087243	0.44	2	CTLA4	Cytotoxic T-lymphocyte protein 4	
	rs934734	0.52	2	SPRED2	Sprouty related, EVH1 domain-containing protein 2	
	rs13315591	0.1	3	PXK	PX domain-containing protein kinase-like protein	
	rs874040	0.033	4	RBPJ	Recombining binding protein suppressor of hairless	
	rs6859219	0.18	5	IL6ST	IL-6 receptor subunit β	
	rs26232	0.29	5	NREP	Neuronal regeneration-related protein	
	rs3093023	0.47	6	CCR6	C–C chemokine receptor type 6	
	rs6920220	0.22	6	TNFAIP3	Tumour necrosis factor α -induced protein 3	
	rs10488631	0.13	7	IRF5	Interferon regulatory factor 5	
	rs951005	0.14	9	CCL21	C–C motif chemokine 21	
	rs706778	0.44	10	IL2RA	IL-2 receptor subunit α	
	rs4810485	0.25	20	CD40	Tumor necrosis factor receptor superfamily member 5	
SSc	rs2056626	0.37	1	CD247	T-cell surface glycoprotein CD3 zeta chain	[98]
	rs3821236	0.25	2	STAT4	Signal transducer and activator of transcription 4	
	rs6457617	0.47	6	HLA-DQB1	HLA class II histocompatibility antigen, DQ β 1 chain	
	rs4959270	0.45	6	IRF4	Interferon regulatory factor 4	
	rs12537284	0.16	7	IRF5	Interferon regulatory factor 5	
	rs10515998	0.06	18	CDH7	Cadherin-7	
Myositis	rs6738825	0.45 ^b	2	PLCL1	Inactive phospholipase C-like protein 1	[99]
	rs2736340	0.36 ^b	8	BLK	Tyrosine-protein kinase Blk	
	rs951005	0.21 ^b	9	CCL21	C–C motif chemokine 21	
	rs32552080	0.21	6	HLA-DRB1	HLA class II histocompatibility antigen, DRB1–14 β chain	
SS	rs10553577	0.3	2	STAT4	Signal transducer and activator of transcription 4	[101]
	rs485497	0.54	3	IL12A	IL-12 subunit α	
	rs6579837	0.12	5	TNIP1	TNFAIP3-interacting protein 1	
	rs112357081	0.59	6	HLA-DRA	HLA class II histocompatibility antigen, DR α chain	
	rs3757387	0.54	7	IRF5	Interferon regulatory factor 5	
	rs2736345	0.36	8	BLK	Tyrosine-protein kinase Blk	
	rs7119038	0.18	11	CXCR5	C–X–C chemokine receptor type 5	

RA, rheumatoid arthritis; SS, Sjogren's syndrome; SSc, systemic sclerosis.

^aBased on population of reference(s) cited. Actual MAF will vary depending on ancestral background of study population.

^bBased on MAF reported by 1000 genomes project (www.1000genomes.org) as no study population frequency reported.

DRUG–GENE INTERACTION IN PATIENTS WITH IPF

The first suggestion of drug–gene interaction in patients with IPF was reported as secondary analyses of a GWAS [74] and survival analysis [93]. DNA samples from patients enrolled in the 'Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis' trial [102] were among those used to conduct our group's recent GWAS. Post hoc analysis of this cohort (reported in the supplement) showed possible interaction between warfarin therapy and the *MUC5B* promoter polymorphism, though the small sample size precluded formal interaction testing. It was observed that among

genotyped trial participants, more deaths occurred in those with the polymorphism who received warfarin compared with placebo (6 warfarin vs. 1 placebo), suggesting a possible interaction.

In their survival analysis of the *MUC5B* promoter polymorphism [93], Peljto and colleagues used DNA samples collected from patients enrolled in 'The INSPIRE Trial: A Study of Interferon γ -1b for Idiopathic Pulmonary Fibrosis' [103]. These authors showed that the survival benefit associated with this polymorphism was stronger among those receiving interferon γ -1b compared with placebo. Although formal interaction analysis failed to cross the significance threshold ($p_{\text{interaction}} = 0.07$), it did raise

the question of whether this therapy may have been more efficacious in those carrying the polymorphism. The authors did point out however that the survival benefit observed with the polymorphism in the INSPIRE cohort would not be expected in the University of Chicago replication cohort if this benefit was due solely to drug–gene interaction.

In December 2015, our group published the first dedicated pharmacogenetic investigation conducted in patients with IPF to date [104^{***}]. This was performed using paired genetic and clinical data from patients enrolled in the ‘Effectiveness of Prednisone, Azathioprine, and N-Acetylcysteine in

Patients with Idiopathic Pulmonary Fibrosis’ (PANTHER) clinical trial [19,105]. Common SNPs within *TOLLIP* and *MUC5B* were genotyped and tested for interaction with trial interventions, including N-acetylcysteine (NAC) monotherapy and combination therapy with prednisone, azathioprine, and NAC, using a composite end point of death, transplantation, hospitalization and $\geq$ at least 10% decline in forced vital capacity.

Using a multivariable Cox proportional hazards model, we identified significant interaction between NAC monotherapy and rs3750920, a coding SNP within exon 3 of *TOLLIP*. Genotype-stratified

FIGURE 1. Composite endpoint-free survival between NAC and placebo groups after stratification by rs3750920 (*TOLLIP*) genotype. In those with a CC genotype (a), NAC therapy is associated with worse survival than placebo ($P_{\text{logrank}} = 0.01$; hazard ratio, 3.23; 95% confidence interval, 0.79–13.16; $P = 0.10$). In those with a CT genotype (b), survival is similar between groups ($P_{\text{logrank}} = 0.82$; HR 0.76; 95% CI 0.27–2.19; $P = 0.62$). In those with a TT genotype (c), NAC therapy is associated with improved survival compared with placebo ($P_{\text{logrank}} = 0.06$; HR 0.14; 95% CI 0.02–0.83; $P = 0.03$). Multivariable Cox regression models adjusted for age, sex, FVC (percentage predicted), and diffusion capacity of the lung for carbon monoxide (percentage predicted) at time of study enrollment. Reproduced from [104^{***}] with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. CI, confidence interval; FVC, forced vital capacity; HR, hazard ratio; NAC, N acetylcysteine.

Kaplan–Meier curves and Cox models were constructed (Fig. 1) and showed that those with a CC genotype had an increased composite end point risk whereas those with a TT genotype had a decreased risk. Sensitivity analysis showed that the increased risk among those with a CC genotype was driven primarily by forced vital capacity decline events, whereas the decreased risk associated with the TT genotype was consistent across all end points. These findings were then replicated in an independent IPF cohort of patients followed at the University of Chicago and enrolled in the INSPIRE clinical trial.

This study had several limitations, including its post hoc, exploratory design and small sample size (<50% of PANTHER participants consented to genetic analysis). Despite these limitations, this study again raised the question of whether NAC may be an efficacious therapy for some patients with IPF and supports the pursuit a genotype-stratified NAC clinical trial. Furthermore, it highlighted the importance of pharmacogenetic investigation in patients with IPF, and ILD in general, and underscored the need for biospecimen collection in this patient population.

CONCLUSION

As medicine strives to usher in an era of personalized medicine, extensive pharmacogenetic investigation will be necessary to make this goal a reality. Prospective, randomized, genotyped-stratified clinical trials have already been conducted in patients with asthma [106,107], and provide a template for implementation in ILD. Prior to formal testing in clinical trials, drug–gene interaction must first be identified using paired DNA and clinical data from patient registries and completed clinical trials. Patient and provider education will be paramount in this endeavor, as biospecimens will be needed for such work and should be collected from as many patients as possible. Equally important will be a coordinated effort among ILD centers, not only to ensure robust pharmacogenetic testing, but to also expand clinical trial access to patients with less common ILDs.

Acknowledgements

None.

Financial support and sponsorship

None.

Conflicts of interest

J.M.O. is currently receiving a grant from the American Thoracic Society and Boehringer Ingelheim outside the submitted work. I.N. is currently receiving a grant from

the NIH and HLR outside the submitted work. He has received honoraria from Boehringer Ingelheim, Gilead/perceptive, Sunovion, PILOT CME and Genentech outside the submitted work. He reports a patent TOLLIP in IPF that is pending, a patent PBMC expression signature in IPF which is pending and patent Plasma proteins in IPF that has been issued. F.J.M. is currently receiving a grant from NIH outside the submitted work. He has received nonfinancial support from Bayer, Centocor, Gilead, Promedior. He reports honoraria from Ikaria, Genentech, Nycomed/Takeda, Pfizer, Vertex, American Thoracic Society, Inova Health System, Medscape, Spectrum Health System, University of Texas Southwestern, Stromedix/Biogen, Axon Communications, Johnson & Johnson, Genzyme, National Association for Continuing Education, Boehringer Ingelheim, Veracyte, Academic CME, UNITY Forest, Janssens, GSK, Nycomed/Takeda, Actelion, Amgen, Astra Zeneca, CSA Medical, Ikaria/Bellerophon, Forest, Merck, Pearl, Roche, Sudler & Hennessey, American College of Chest Physicians, CME Incite, Center for Healthcare Education, Inova Health System, Miller Medical, National Association for Continuing Education, Paradigm, Peer Voice, Projects in Knowledge, St. John's Hospital, St. Mary's Hospital, University of Illinois Chicago, Up To Date, Wayne State University, Grey Healthcare, Merion, Informa, Annenberg, Theravance outside the submitted work.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? *Clin Genet* 1999; 56:247–258.
2. Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia, USA: W.B. Saunders; 1962.
3. Lindpaintner K. Pharmacogenetics and the future of medical practice: conceptual considerations. *Pharmacogenomics J* 2001; 1:23–26.
4. Martis S, Mei H, Vijzelaar R, *et al.* Multiethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. *Pharmacogenomics J* 2013; 13:558–566.
5. Winkelmann BR, Nauck M, Klein B, *et al.* Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. *Ann Intern Med* 1996; 125:19–25.
6. Tantisira KG, Lazarus R, Litonjua AA, *et al.* Chromosome 17: association of a large inversion polymorphism with corticosteroid response in asthma. *Pharmacogenet Genomics* 2008; 18:733–737.
7. Choudhry S, Ung N, Avila PC, *et al.* Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. *Am J Respir Crit Care Med* 2005; 171:563–570.
8. Israel E, Drazen JM, Liggett SB, *et al.* The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. *Am J Respir Crit Care Med* 2000; 162:75–80.
9. Martinez FD, Graves PE, Baldini M, *et al.* Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. *J Clin Invest* 1997; 100:3184–3188.
10. Wechsler ME, Lehman E, Lazarus SC, *et al.* β -adrenergic receptor polymorphisms and response to salmeterol. *Am J Respir Crit Care Med* 2006; 173:519–526.
11. Hizawa N, Makita H, Nasuhara Y, *et al.* β 2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. *Chest* 2007; 132:1485–1492.

12. Umeda N, Yoshikawa T, Kanazawa H, *et al.* Association of β 2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. *Respirology* 2008; 13:346–352.
13. Kim WJ, Hersh CP, DeMeo DL, *et al.* Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. *Respir Med* 2009; 103:552–557.
14. King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. *Am J Respir Crit Care Med* 2005; 172:268–279.
15. Bjoraker JA, Ryu JH, Edwin MK, *et al.* Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998; 157:199–203.
16. Flaherty KR, Toews GB, Travis WD, *et al.* Clinical significance of histological classification of idiopathic interstitial pneumonia. *Eur Respir J* 2002; 19:275–283.
17. Strand MJ, Sprunger D, Cosgrove GP, *et al.* Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. *Chest* 2014; 146:775–785.
18. Berezne A, Ranque B, Valeyre D, *et al.* Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. *J Rheumatol* 2008; 35:1064–1072.
19. Raghu G, Anstrom KJ, King TE Jr, *et al.* Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *N Engl J Med* 2012; 366:1968–1977.
20. Coultas DB, Hughes MP. Accuracy of mortality data for interstitial lung diseases in New Mexico, USA. *Thorax* 1996; 51:717–720.
21. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. *Science* 1999; 286:487–491.
22. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. *N Engl J Med* 2005; 353:1711–1723.
23. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. *Chest* 2013; 143:814–824.
24. Krupoves A, Mack D, Deslandes C, *et al.* Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn's disease. *Pharmacogenet Genomics* 2011; 21:454–460.
25. Baker AC, Green TL, Chew VW, *et al.* Enhanced steroid response of a human glucocorticoid receptor splice variant. *Shock* 2012; 38:11–17.
26. Tantisira KG, Lake S, Silverman ES, *et al.* Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. *Hum Mol Genet* 2004; 13:1353–1359.
27. Hawkins GA, Lazarus R, Smith RS, *et al.* The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. *J Allergy Clin Immunol* 2009; 123:1376–1383.
28. Tantisira KG, Hwang ES, Raby BA, *et al.* TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. *Proc Natl Acad Sci U S A* 2004; 101:18099–18104.
29. Rojas-Serrano J, Gonzalez-Velasquez E, Mejia M, *et al.* Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. *Reumatol Clin* 2012; 8:68–71.
30. Deheinzlin D, Capelozzi VL, Kairalla RA, *et al.* Interstitial lung disease in primary Sjogren's syndrome. Clinical-pathological evaluation and response to treatment. *Am J Respir Crit Care Med* 1996; 154:794–799.
31. Dheda K, Laloo UG, Cassim B, *et al.* Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. *Clin Rheumatol* 2004; 23:306–309.
32. Paone C, Chiarolanza I, Cuomo G, *et al.* Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. *Clin Exp Rheumatol* 2007; 25:613–616.
33. Sauty A, Rochat T, Schoch OD, *et al.* Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. *Eur Respir J* 1997; 10:2907–2912.
34. Bunch TW, Worthington JW, Combs JJ, *et al.* Azathioprine with prednisone for polymyositis. A controlled, clinical trial. *Ann Intern Med* 1980; 92:365–369.
35. Bunch TW. Prednisone and azathioprine for polymyositis: long-term follow-up. *Arthritis Rheum* 1981; 24:45–48.
36. Ujiie S, Sasaki T, Mizugaki M, *et al.* Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 - *24). *Pharmacogenet Genomics* 2008; 18:887–893.
37. Liu YP, Xu HQ, Li M, *et al.* Association between thiopurine s-methyltransferase polymorphisms and azathioprine-induced adverse drug reactions in patients with autoimmune diseases: a meta-analysis. *PLoS One* 2015; 10:e0144234.
38. Gleeson D, Heneghan MA. British Society of G. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. *Gut* 2011; 60:1611–1629.
39. Manns MP, Czaja AJ, Gorham JD, *et al.* Diagnosis and management of autoimmune hepatitis. *Hepatology* 2010; 51:2193–2213.
40. Meggitt SJ, Anstey AV, Mohd Mustapa MF, *et al.* British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine. *Br J Dermatol* 2011; 165:711–734.
41. Relling MV, Gardner EE, Sandborn WJ, *et al.* Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther* 2011; 89:387–391.
42. Smith MA, Marinaki AM, Arenas M, *et al.* Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. *Aliment Pharmacol Ther* 2009; 30:375–384.
43. Fischer A, Brown KK, Du Bois RM, *et al.* Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. *J Rheumatol* 2013; 40:640–646.
44. Swigris JJ, Olson AL, Fischer A, *et al.* Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. *Chest* 2006; 130:30–36.
45. Tzouveleki A, Galanopoulos N, Bouros E, *et al.* Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. *Pulm Med* 2012; 2012:143637.
46. Winnicki W, Weigel G, Sunder-Plassmann G, *et al.* An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. *Pharmacogenomics J* 2010; 10:70–76.
47. Kuypers DR, Naesens M, Vermeire S, *et al.* The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. *Clin Pharmacol Ther* 2005; 78:351–361.
48. Kurita T, Yasuda S, Oba K, *et al.* The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. *Rheumatology (Oxford)* 2015; 54:39–44.
49. Wilkes MR, Sereika SM, Fertig N, *et al.* Treatment of antisyntetase-associated interstitial lung disease with tacrolimus. *Arthritis Rheum* 2005; 52:2439–2446.
50. Witt LJ, Demchuck C, Curran JJ, *et al.* Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. *Pulm Pharmacol Ther* 2016; 36:46–52.
51. Tavora B, Coto E, Diaz-Corte C, *et al.* Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. *Clin Chem Lab Med* 2011; 49:825–833.
52. Lopez-Montenegro Soria MA, Kanter Berga J, Beltran Catalan S, *et al.* Genetic polymorphisms and individualized tacrolimus dosing. *Transplant Proc* 2010; 42:3031–3033.
53. Richeldi L, du Bois RM, Raghu G, *et al.* Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370:2071–2082.
54. King TE Jr, Bradford WZ, Castro-Bernardini S, *et al.* A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370:2083–2092.
55. Noble PW, Albera C, Bradford WZ, *et al.* Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet* 2011; 377:1760–1769.
56. Conte E, Gili E, Fagone E, *et al.* Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. *Eur J Pharm Sci* 2014; 58:13–19.
57. Nakayama S, Mukae H, Sakamoto N, *et al.* Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. *Life Sci* 2008; 82:210–217.
58. Kruit A, Grutters JC, Ruven HJ, *et al.* Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. *Chest* 2006; 129:1584–1591.
59. Armendariz-Borunda J, Rincon AR, Munoz-Valle JF, *et al.* Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. *J Investig Med* 2008; 56:944–953.
60. Wollin L, Wex E, Pautsch A, *et al.* Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. *Eur Respir J* 2015; 45:1434–1445.
61. Heinzel C, Gsur A, Hunjadi M, *et al.* Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. *Cancer Res* 2012; 72:5767–5777.
62. Easton DF, Pooley KA, Dunning AM, *et al.* Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* 2007; 447:1087–1093.
63. Kim MJ, Kim SK, Park HJ, *et al.* PDGFRA promoter polymorphisms are associated with the risk of papillary thyroid cancer. *Mol Med Rep* 2012; 5:1267–1270.
64. Low SK, Takahashi A, Mushirola T, *et al.* Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. *Clin Cancer Res* 2014; 20:2541–2552.
65. Nogee LM, Dunbar AE 3rd, Wert SE, *et al.* A mutation in the surfactant protein C gene associated with familial interstitial lung disease. *N Engl J Med* 2001; 344:573–579.
66. Thomas AQ, Lane K, Phillips J 3rd, *et al.* Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. *Am J Respir Crit Care Med* 2002; 165:1322–1328.

67. van Moersel CH, van Oosterhout MF, Barlo NP, *et al.* Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. *Am J Respir Crit Care Med* 2010; 182:1419–1425.
 68. Ono S, Tanaka T, Ishida M, *et al.* Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. *Eur Respir J* 2011; 38:861–869.
 69. Wang Y, Kuan PJ, Xing C, *et al.* Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. *Am J Hum Genet* 2009; 84:52–59.
 70. Armanios MY, Chen JJ, Cogan JD, *et al.* Telomerase mutations in families with idiopathic pulmonary fibrosis. *N Engl J Med* 2007; 356:1317–1326.
 71. Tsakiri KD, Cronkhite JT, Kuan PJ, *et al.* Adult-onset pulmonary fibrosis caused by mutations in telomerase. *Proc Natl Acad Sci U S A* 2007; 104:7552–7557.
 72. Cogan JD, Kropski JA, Zhao M, *et al.* Rare variants in RTEL1 are associated with familial interstitial pneumonia. *Am J Respir Crit Care Med* 2015; 191:646–655.
- The study identified rare mutations within *RTEL1*, encodes an important regulator of telomere elongation, to be associated with FIP, the heritable form of IPF. This work adds to the growing body of literature that implicates telomere instability in the development of pulmonary fibrosis.
73. Stuart BD, Choi J, Zaidi S, *et al.* Exome sequencing links mutations in PARN with familial pulmonary fibrosis and telomere shortening. *Nat Genet* 2015; 47:512–517.
- The study identified rare mutations within *RTEL1* along with PARN, which encodes a exoribonuclease involved in mRNA processing, to be associated with FIP. This is the first investigation to link mutations in PARN to IPF.
74. Noth I, Zhang Y, Ma S-F, *et al.* Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. *The Lancet* 2013; 1:309–317.
 75. Seibold MA, Wise AL, Speer MC, *et al.* A common MUC5B promoter polymorphism and pulmonary fibrosis. *N Engl J Med* 2011; 364:1503–1512.
 76. Fingerlin TE, Murphy E, Zhang W, *et al.* Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nat Genet* 2013; 45:613–620.
 77. Mushihiro T, Wattanapokayakit S, Takahashi A, *et al.* A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. *J Med Genet* 2008; 45:654–656.
 78. Ahn MH, Park BL, Lee SH, *et al.* A promoter SNP rs4073T>A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. *Respir Res* 2011; 12:73.
 79. Barlo NP, van Moersel CH, Korthagen NM, *et al.* Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis. *Clin Exp Immunol* 2011; 166:346–351.
 80. Whyte M, Hubbard R, Meliconi R, *et al.* Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. *Am J Respir Crit Care Med* 2000; 162:755–758.
 81. Xue J, Gochuico BR, Alawad AS, *et al.* The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. *PLoS One* 2011; 6:e14715.
 82. Aquino-Galvez A, Gonzalez-Avila G, Perez-Rodriguez M, *et al.* Analysis of heat shock protein 70 gene polymorphisms Mexican patients with idiopathic pulmonary fibrosis. *BMC Pulm Med* 2015; 15:129.
- The most recent study to identify polymorphisms associated with IPF susceptibility and the first to link SNPs within the 70 kDa heat shock proteins to this disease.
83. Korthagen NM, van Moersel CH, Barlo NP, *et al.* Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. *PLoS One* 2012; 7:e30442.
 84. O'Dwyer DN, Armstrong ME, Trujillo G, *et al.* The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2013; 188:1442–1450.
 85. Xaubet A, Marin-Arguedas A, Lario S, *et al.* Transforming growth factor-β1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2003; 168:431–435.
 86. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. *J Biol Chem* 2002; 277:7059–7065.
 87. Pruitt KD, Brown GR, Hiatt SM, *et al.* RefSeq: an update on mammalian reference sequences. *Nucleic Acids Res* 2014; 42:D756–D763.
 88. Shah JA, Vary JC, Chau TT, *et al.* Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. *J Immunol* 2012; 189:1737–1746.
 89. Saito T, Yamamoto T, Kazawa T, *et al.* Expression of toll-like receptor 2 and 4 in lipopolysaccharide-induced lung injury in mouse. *Cell Tissue Res* 2005; 321:75–88.
 90. Janardhan KS, McIsaac M, Fowle J, *et al.* Toll like receptor-4 expression in lipopolysaccharide induced lung inflammation. *Histol Histopathol* 2006; 21:687–696.
 91. Roy MG, Livraghi-Butrico A, Fletcher AA, *et al.* Muc5b is required for airway defence. *Nature* 2014; 505:412–416.
 92. Molyneux PL, Cox MJ, Willis-Owen SA, *et al.* The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2014; 190:906–913.
 93. Peljto AL, Zhang Y, Fingerlin TE, *et al.* Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *JAMA* 2013; 309:2232–2239.
 94. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011; 183:431–440.
 95. Selman M, Carrillo G, Estrada A, *et al.* Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. *PLoS One* 2007; 2:e482.
 96. Nathan SD, Shlobin OA, Weir N, *et al.* Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. *Chest* 2011; 140:221–229.
 97. Stahl EA, Raychaudhuri S, Remmers EF, *et al.* Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet* 2010; 42:508–514.
 98. Radstake TR, Gorlova O, Rueda B, *et al.* Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. *Nat Genet* 2010; 42:426–429.
 99. Miller FW, Cooper RG, Vencovsky J, *et al.* Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. *Arthritis Rheum* 2013; 65:3239–3247.
 100. Miller FW, Chen W, O'Hanlon TP, *et al.* Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. *Genes Immun* 2015; 16:470–480.
 101. Lessard CJ, Li H, Adrianto I, *et al.* Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. *Nat Genet* 2013; 45:1284–1292.
 102. Noth I, Anstrom KJ, Calvert SB, *et al.* A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2012; 186:88–95.
 103. King TE Jr, Albera C, Bradford WZ, *et al.* Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multi-centre, randomised, placebo-controlled trial. *Lancet* 2009; 374:222–228.
 104. Oldham JM, Ma SF, Martinez FJ, *et al.* TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2015; 192:1475–1482.
- The first dedicated pharmacogenetic investigation in patients with interstitial lung disease and identifies a variant within TOLLIP to be associated with differential response to NAC therapy. This study identifies a subgroup of genetically predisposed individuals with IPF who may respond to NAC therapy, which was previously shown to be ineffective in the treatment of IPF.
105. Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370:2093–2101.
 106. Israel E, Chinchilli VM, Ford JG, *et al.* Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. *Lancet* 2004; 364:1505–1512.
 107. Wechsler ME, Kunselman SJ, Chinchilli VM, *et al.* Effect of β2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, cross-over trial. *Lancet* 2009; 374:1754–1764.